Alzex Neuropharma EBIT

Alzex Neuropharma (TRRI) currently reports a EBIT of $-410K as of June 2024. That compares with $-280K in the prior-year period — down 47.8% year over year. That is below the sector sector average of $2.5T. Use the charts on this page to explore Alzex Neuropharma's EBIT history and peer comparisons.

Alzex Neuropharma's EBIT decreased from $-280K to $-410K — a 47.8% year-over-year decrease (period ending June 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Alzex Neuropharma's EBIT of $-410K is lower than the its sector sector average of $2.5T. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Alzex Neuropharma reported $-410K in EBIT as of June 2024. That compares with $-280K in the prior-year period — down 47.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-410K, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $2.5T. From there, open related valuation or income-statement pages for Alzex Neuropharma, and consider following TRRI for alerts when major investors trade the stock.